AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates.
It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract.
The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Country | United States |
IPO Date | Jun 30, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 163 |
CEO | Dr. Bruce Culleton M.D. |
Contact Details
Address: 2000 Frontis Plaza Blvd. Winston-Salem, North Carolina United States | |
Website | https://www.prokidney.com |
Stock Details
Ticker Symbol | PROK |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001850270 |
CUSIP Number | n/a |
ISIN Number | KYG7S53R1049 |
Employer ID | 98-1586514 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Bruce Culleton M.D. | Chief Executive Officer & Director |
Carla Poulson | Chief People Officer |
James Coulston CPA | Chief Financial Officer |
Todd C. Girolamo Esq., J.D., M.B.A. | Chief Legal Officer & Secretary |
Anu Biswas | Senior Vice President of Manufacturing & Operations |
Dr. Darin J. Weber Ph.D. | Chief Reg. Off, SVice President and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access |
Dr. Joseph M. Stavas M.D., M.P.H. | SVice President of Clinical Affairs |
Dr. Timothy A. Bertram D.V.M., Ph.D. | Founder |
Dr. Ulrich Ernst Ph.D. | EVice President of Science and Technology |
Nikhil L. Pereira-Kamath | Chief Business Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 22, 2024 | 8-K | Current Report |
Nov 12, 2024 | 10-Q | Quarterly Report |
Nov 12, 2024 | 8-K | Current Report |
Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Oct 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Oct 22, 2024 | 3 | Filing |
Oct 18, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Sep 20, 2024 | 4 | Filing |
Sep 16, 2024 | 4 | Filing |